Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Bioshares Biotech Summit 2024
21 slides from Pyc Therapeutics's conference presentation, Jul 12, 2024
Slide 1: Bioshares Biotech Summit Presentation
12 July 2024 BIOSHARES BIOTECH SUMMIT PRESENTATION PERTH, Australia and SAN FRANCISCO, California – 12 July 2024 PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC’s CEO, Dr Rohan Hockings, at the Bioshares Biotech Summit, 12 July 2024. For
Slide 2: Life-changing science: Bioshares Biotech Summit July 2024
For personal use only Life-changing science Bioshares Biotech Summit July 2024
Slide 3: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 4: Today's topics
Today’s topics For personal use only • An introduction to PYC Therapeutics • An outline of PYC’s ambition – how 2024 will evolve into 2025 • How the pipeline was built around: • High propensity programs; with • A high-velocity path to market • Why now is the critical time for the Company – illustrat
Slide 5: Company introduction
For personal use only Life-changing science Company introduction
Slide 6: An introduction to PYC Therapeutics
An introduction to PYC Therapeutics • PYC is a clinical-stage drug discovery and development company with operations in Australia For personal use only and the US • The company is an emerging leader in the field of precision RNA therapies for patients with genetic diseases caused by haploinsufficien
Slide 7: The evolution of PYC's ambition through 2025
For personal use only Life-changing science The evolution of PYC’s ambition through 2025
Slide 8: PYC is currently conducting clinical trials in parallel
PYC is currently conducting 5 clinical trials in parallel Indication Trial Early Mid Late For personal use only 1) Retinitis Pigmentosa type 11 1) Natural History Ongoing 2) SAD 3) MAD 2) Autosomal Dominant Optic Atrophy 1) Natural History Ongoing 2) SAD1 Expected Q3 2024 SAD: Single Ascending Dose;
Slide 9: There is scope for this clinical pipeline to grow substantially in 2025
There is scope for this clinical pipeline to grow substantially in 20251 Indication Trial Early Mid Late For personal use only 1) Retinitis Pigmentosa type 11 1) Natural History Ongoing 2) SAD 3) MAD 4) Pivotal 2) Autosomal Dominant Optic Atrophy 1) Natural History Ongoing 2) SAD1 Expected Q3 2024 3
Slide 10: Building a pipeline (with a critical difference)
For personal use only Life-changing science Building a pipeline (with a critical difference)
Slide 11: Two elements that change the probability of success in the clinic
There are two elements embedded within PYC’s pipeline that fundamentally change the probability of success in the clinic For personal use only 1 PYC pursues diseases caused by mutations in a single gene (‘monogenic’ diseases) 2 PYC validates its drug candidates in human target tissue before it progr
Slide 12: Monogenic drugs that enter human trials are 5x more likely to succeed
1. Monogenic drugs that enter human trials are 5x more likely to succeed1 For personal use only 100 Monogenic Profile Industry Standard Profile 80 Probability of Success (%)2 60 40 1 5x 20 0 Discovery Pre-clinical Translational Phase 1 Phase 2 Phase 3 PYC THERAPEUTICS 11 1. Advancing Human Genetics
Slide 13: PYC validates all pipeline candidates in patient-derived models
2. PYC validates all pipeline candidates in patient-derived models before it enters clinical development 1. PYC can create a patient-derived retina Retinitis Pigmentosa type RP11 treated For personal use only 11 (RP11) untreated with VP-001 i. PRPF31 PRPF31 That enables it to determine whether its d
Slide 14: Validation in patient-derived models further enhances probability of success
Validation of PYC’s drug candidates in patient-derived models further enhances their probability of success in the clinic 100 For personal use only Monogenic Profile Industry Standard Profile 80 Probability of Success (%)2 2 60 40 5x 20 0 Discovery Pre-clinical Translational Phase 1 Phase 2 Phase 3
Slide 15: PYC's strategy: best-in-class assets with high probability of success
PYC’s strategy sees it developing best-in-class assets with a high probability of success in the clinic For personal use only 1 2 3 4 Pillar Single gene disorders Effective in human 3D Haploinsufficient Drugs that overcome ‘mini-organs’ disease mechanism the delivery challenge3 Clinical insights Hig
Slide 16: RP11 – illustrating the potential for patient impact
For personal use only Life-changing science RP11 – illustrating the potential for patient impact
Slide 17: In focus: first drug candidate for a blinding eye disease in human trials
In focus: PYC has progressed the first drug candidate for patients with a blinding eye disease into human trials For personal use only Historical progress Progress expected in 2024 Program Pre-clinical Clinical Prevalence and Market Size*^ VP-001* Retinitis Pigmentosa Type 11 Today’s focus 1 in 100,
Slide 18: Data integration sets a strong platform leading into human efficacy read-outs
The integration of the data generated to date sets a strong platform leading into PYC’s human efficacy read-outs For personal use only Pre-clinical Clinical ? RP11 Patient-derived models Non-human primate RP11 Patient RP11 Patient RP11 Patient Safety and efficacy1 Safety and high drug Safety3 Early
Slide 19: PYC is translating these outcomes into patients now
PYC is translating these outcomes into patients now PYC’s path to market is staged with human data read-outs for first-in-class drugs with disease-modifying potential1 For personal use only Program 2024 2025 2026 2027 2028 RP11 Ph1/2 study (underway) Registrational study NDA Product launch and VP-00
Slide 20: References
For personal use only Life-changing science References
Slide 21: Prevalence references
Prevalence references Program References for prevalence estimate For personal use only Retinitis Pigmentosa • Daiger S, et al. ‘Genes and Mutations Causing Autosomal Dominant Retinitis Pigmentosa’ Cold Spring Harb. Perspect. Med. 2014;5 • Ellingford J, et al. ‘Molecular findings from 537 individuals